.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,066,660

« Back to Dashboard

Details for Patent: 5,066,660

Title: Indole derivatives
Abstract:Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents H or C.sub.1-6 alkyl; R.sub.2 represents H, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phen(C.sub.1-3)alkyl in which the phenyl ring is optionally substituted by halogen, C.sub.1-4 alkoxy, hydroxy or C.sub.1-3 alkyl; R.sub.3 represents H, C.sub.1-3 alkyl, --CO.sub.2 R.sub.5, --COR.sub.5, --COCO.sub.2 R.sub.5 or --CONHR.sub.5 where R.sub.5 represents H, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-4 alkenyl, aryl or ar(C.sub.1-4)alkyl in which the aryl group is optionally substituted by halogen, C.sub.1-4 alkoxy, C.sub.1-4 alkyl or hydroxy) (provided that where R.sub.3 represents --CO.sub.2 R.sub.5, R.sub.5 is other than H); R.sub.4 represents H, C.sub.1-3 alkyl, C.sub.3-6 alkenyl, phenyl or phen (C.sub.1-3)alkyl; A-B represents CH--CH.sub.2 --or C.dbd.CH-- D represents --CO-- or --SO.sub.2 -- n represents 0, 1-5; provided that when D represents --SO.sub.2, n is 2, R.sub.3 represents H and R.sub.4 represents H or C.sub.1-3 alkyl, R.sub.2 is other than H or C.sub.1-6 alkyl; and pharmaceutically acceptable salts and solvates (for example hydrates) thereof. The compounds are indicated as useful for the treatment of migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders. Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.
Inventor(s): Oxford; Alexander W. (Hertford, GB2), Coates; Ian H. (Hertford, GB2), Butina; Darko (Bedfordshire, GB2)
Assignee: Glaxo Group Limited (London, GB2)
Filing Date:Aug 21, 1990
Application Number:07/570,513
Claims:1. A compound of formula (I) ##STR13## wherein R.sub.1 represents a hydrogen atom, or a C.sub.1-6 alkyl group;

R.sub.2 represents a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-7 cycloalkyl group, a C.sub.3-6 alkenyl group, or a phenyl or phen(C.sub.1-3) alkyl group in which the phenyl ring is optionally substituted by a halogen atom, a C.sub.1-4 alkoxy group, a hydroxy group or a C.sub.1-3 alkyl group;

R.sub.3 represents a hydrogen atom, a C.sub.1-3 alkyl group or a group --CO.sub.2 R.sub.5, --COR.sub.5, --COCO.sub.2 R.sub.5 or --CONHR.sub.5, where R.sub.5 represents a hydrogen atom, a C.sub.1-4 alkyl group, a C.sub.3-7 cycloalkyl group, a C.sub.2-4 alkenyl group or an aryl or ar(C.sub.1-4)alkyl group in which the aryl group is phenyl which may be unsubstituted or substituted by a halogen atom, a C.sub.1-4 alkoxy group, a C.sub.1-4 alkyl group or a hydroxy group, provided that when R.sub.3 represents --CO.sub.2 R.sub.5,

R.sub.5 is other than hydrogen;

R.sub.4 represents a hdyrogen atom, a C.sub.1-3 alkyl group, a C.sub.3-6 alkenyl group, a phenyl group or a phen(C.sub.1-3)alkyl group;

A--B represents the group CH--CH.sub.2 -- or C.dbd.CH--;

D represents the group --SO.sub.2 --;

n represents zero or an integer from 1 to 5;

or a pharmaceutically acceptable salt or solvate thereof, provided that when n is 2, R.sub.3 is hydrogen and R.sub.4 is hydrogen or C.sub.1-3 alkyl, then R.sub.2 is other than hydrogen or C.sub.1-6 alkyl.

2. A compound according to claim 1, wherein, in the formula (I), A--B represents the group --CH--CH.sub.2 --.

3. A compound according to claim 1, wherein, in the formula (I), R.sub.1 represents a hydrogen atom or a C.sub.1-3 alkyl group.

4. A compound according to claim 1, wherein, in the formula (I), R.sub.2 represents a hydrogen atom or a C.sub.1-3 alkyl group.

5. A compound according to claim 1, wherein, in the formula (I), R.sub.1 and R.sub.2 together comprise from 1 to 3 carbon atoms, and when R.sub. and R.sub.2 comprise 1 carbon atom, then one of R.sub.1 or R.sub.2 is hdyrogen.

6. A compound according to claim 1, wherein, in the formula (I), R.sub.3 represents a hydrogen atom.

7. A compound according to claim 1, wherein, in the formula (I), R.sub.4 represents a C.sub.1-3 alkyl group.

8. A compound according to claim 1, wherein, in the formula (I), n represents 0, 1 or 2.

9. A compound according to claim 1, wherein in formula (I), n represents 1,2,3,4 or 5.

10. A compound of formula (I) ##STR14## wherein R.sub.1 represents a hydrogen atom or a C.sub.1-6 alkyl group;

R.sub.2 represents a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-7 cycloalkyl group, a C.sub.3-6 alkenyl group, or a phenyl or phen(C.sub.1-3) alkyl group in which the phenyl ring is optionally substituted by a halogen atom, a C.sub.1-4 alkoxy group, a hydroxy group or a C.sub.1-3 alkyl group;

R.sub.3 represents a hydrogen atom, a C.sub.1-3 alkyl group or a group --CO.sub.2 R.sub.5, --COR.sub.5, --COCO.sub.2 R.sub.5 or --CONHR.sub.5, where R.sub.5 represents a hydrogen atom, a C.sub.1-4 alkyl group, a C.sub.3-7 cycloalkyl group, a C.sub.2-4 alkenyl group or an aryl or ar(C.sub.1-4)alkyl group in which the aryl group is phenyl which is phenyl which may be unsubstituted or substituted by a halogen atom, a C.sub.1-4 alkoxy group, a C.sub.1-4 alkyl group or a hydroxy group, provided that when R.sub.3 represents --CO.sub.2 R.sub.5, R.sub.5 is other than hydrogen;

R.sub.4 represents a hydrogen atom, a C.sub.1-3 alkyl group, a C.sub.3-6 alkenyl group, a phenyl group or a phen(C.sub.1-3)alkyl group;

A--B represents the group CH--CH.sub.2 -- or C.dbd.CH--;

D represents the group --SO.sub.2 -- or --CO--;

n represents the integer from 1 to 5;

or a pharmaceutically acceptable salt or solvate thereof, provided that when n is 2, R.sub.3 is hydrogen and R.sub.4 is hydrogen or C.sub.1-3 alkyl, then R.sub.2 is other than hydrogen or C.sub.1-6 alkyl.

11. A compound according to claim 10, wherein in formula (I), D represents the group --SO.sub.2 --.

12. A compound according to claim 10, wherein in formula (I), D represents the group --CO--.

13. A compound according to claim 10, wherein in formula (I), A--B represents the group --CH--CH.sub.2 --.

14. A compound according to claim 10, wherein in formula (I), R.sub.1 represents a hydrogen atom or a C.sub.1-3 alkyl group.

15. A compound according to claim 10, wherein in formula (I), R.sub.2 represents a hydrogen atom or a C.sub.1-3 alkyl group.

16. A compound according to claim 10, wherein, in the formula (I), R.sub.1 and R.sub.2 together comprise from 1 to 3 carbon atoms, and when R.sub.1 and R.sub.2 comprise 1 carbon atom, then one of R.sub.1 or R.sub.2 is hydrogen.

17. A compound according to claim 9, wherein in formula (I), R.sub.3 represents a hydrogen atom.

18. A compound according to claim 9, wherein in formula (I), R.sub.4 represents a C.sub.1-3 alkyl group.

19. A compound according to claim 9, wherein in formula (I), n represents 1 or 2.

20. A compound of formula (Ia) ##STR15## wherein R.sub.1a represents a hydrogen atom or a C.sub.1-6 alkyl group;

R.sub.2a represents a hydrogen atom or a C.sub.1-6 alkyl group;

R.sub.3a represents a hydrogen atom or a C.sub.1-3 alkyl group;

R.sub.4a represents a hydrogen atom or a C.sub.1-3 alkyl group;

or a pharmaceutically acceptable salt or solvate thereof.

21. A pharmaceutical composition for use in the treatment of conditions associated with cephalic pain which comprises an effective amount to treat conditions associated with cephalic pain of at least one compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers or excipients.

22. A pharmaceutical composition as claimed in claim 21 wherein the conditions associated with cephalic pain are migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders.

23. A pharmaceutical composition as claimed in claim 21 adapted for oral, parenteral or intranasal administration.

24. A method of treating a human susceptible to or suffering from migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorder which comprises administering an effective amount of a compound of formula (I) ##STR16## wherein R.sub.1 represents a hydrogen atom or a C.sub.1-6 alkyl group;

R.sub.2 represents a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-7 cycloalkyl group, a C.sub.3-6 alkenyl group, or a phenyl or phen(C.sub.1-3)alkyl group in which the phenyl ring is optionally substituted by a halogen atom, a C.sub.1-4 alkoxy group, a hydroxy group or a C.sub.1-3 alkyl group;

R.sub.3 represents a hydrogen atom, a c.sub.1-3 alkyl group or a group --CO.sub.2 R.sub.5, --COR.sub.5, --COCO.sub.2 R.sub.5 or --CONHR.sub.5 wherein R.sub.5 represents a hydrogen atom, a C.sub.1-4 alkyl group, a C.sub.3-7 cycloalkyl group, a C.sub.2-4 alkenyl group or an aryl or ar(C.sub.1-4)alkyl group in which the aryl group may be unsubstituted or substituted by a halogen atom, a C.sub.1-4 alkoxy group, a C.sub.1-4 alkyl group or a hydroxy group (provided that when R.sub.3 represents --CO.sub.2 R.sub.5, R.sub.5 is other than hydrogen)

R.sub.4 represents a hydrogen atom, a C.sub.1-3 alkyl group, a c.sub.3-6 alkenyl group, a phenyl group or a phen(C.sub.1-3)alkyl group;

A--B represents the group CH--CH.sub.2 -- or C.dbd.CH--;

D represents the group --CO-- or --SO.sub.2 --;

n represents zero or an integer from 1 to 5;

provided that when D represents the group --SO.sub.2 --, n is 2, R.sub.3 is hydrogen and R.sub.4 is hydrogen or C.sub.1-3 alkyl, then R.sub.2 is other than hydrogen or C.sub.1-6 alkyl;

or a pharmaceutically acceptable salt or solvate thereof to said human.

25. A method of treating a human susceptible to or suffering from migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders which comprises administering a pharmaceutical composition according to claim 21.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc